Market Signal Briefing

December 01, 2025 8:00 AM EST | Source: Burcon NutraScience Corporation
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein innovation, is pleased to announce that the Company insiders ("Insiders") have increased their commitment to participating in the previously announced non-brokered private placement (the "Offering") (see news release of the Company dated November 12, 2025) of convertible debentures (the "Convertible Debentures").

"Burcon insiders and its largest shareholders have once again shown confidence in our business plan and sales trajectory by expanding their investment," said Kip Underwood, Burcon's chief executive officer. "Their continued support underscores the commercial momentum we carry into 2026 and reinforces our ability to execute and deliver value for shareholders."

Burcon previously announced insider participation at a minimum of $2.0 million in principal amount. Since November 12, 2025, Burcon has received strong interest from potential investors in the Offering including increased interest from Insiders. Burcon anticipates the increased insider participation in the Offering could necessitate disinterested shareholder approval.

The Offering was expected to close on or about November 28, 2025. Given the increased interest in the Offering and the timing required to obtain shareholder approval, the timeline for closing the Offering will be extended. The Company is working with its key investors to finalize the terms and conditions of the Offering, which may change from what was previously announced. The Offering is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX and disinterested shareholders.

About Burcon NutraScience Corporation

Burcon is a global technology leader in high-performance plant-based proteins for the food and beverage industry. Our commercial ingredients offer superior taste, texture, and functionality—ideal for formulators seeking next-generation protein solutions. Backed by over two decades of innovation, Burcon holds an extensive patent portfolio covering novel proteins derived from pea, canola, soy, hemp, sunflower, and other plant sources. As a key player in the rapidly growing plant-based market, Burcon is committed to sustainability and to creating best-in-class protein solutions that are better for people and the planet. Learn more at www.burcon.ca.

Forward-Looking Information Cautionary Statement
The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation, including statements relating to insider participation in the private placement. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as "anticipate," "aim", "intend," "plan," "goal," "project," "estimate," "expect," "believe," "future," "likely," "may," "should," "could," "will" and similar references to future periods. All statements included in this release, other than statements of historical fact, are forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the implementation of our business model and growth strategies; trends and competition in our industry our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations, and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form for the year ended March 31, 2025 and its other public filings with Canadian securities regulators on SEDAR+ at www.sedarplus.ca. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements or information. Any forward-looking statement or information speaks only as of the date on which it was made, and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and, accordingly, investors should not rely on such statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276404

STMicroelectronics announces status
of common share repurchase program

Disclosure of Transactions in Own Shares – Period from November 24, 2025 to November 25, 2025

AMSTERDAM – December 01, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved by a shareholder resolution dated May 22, 2024 and by the supervisory board.

STMicroelectronics N.V. (registered with the trade register under number 33194537) (LEI: 213800Z8NOHIKRI42W10) announces the repurchase (by a broker acting for the Company) on the regulated market of Euronext Paris, in the period between November 21, 2025 to November 25, 2025 (the “Period”), of 206,478 ordinary shares (equal to 0.02% of its issued share capital) at the weighted average purchase price per share of EUR 19.1345 and for an overall price of EUR    3,950,859.05.

The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from share option programmes, or other allocations of shares, to employees or to members of the administrative, management or supervisory bodies of the issuer or of an associate company.

The shares may be held in treasury prior to being used for such purpose and, to the extent that they are not ultimately needed for such purpose, they may be used for any other lawful purpose under article 5(2) of the Market Abuse Regulation.

Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

 Transactions in Period

Dates of transactionNumber of shares purchasedWeighted average purchase price per share (EUR)Total amount paid (EUR)Market on which the shares were bought (MIC code)24-Nov-25 121,609 19.1007 2,322,817.03 XPAR25-Nov-25 84,869 19.1830 1,628,042.03 XPARTotal for Period206,478 19.1345 3,950,859.05   Following the share buybacks detailed above, the Company holds in total 22,535,661 treasury shares, which represents approximately 2.5% of the Company’s issued share capital.

In accordance with Article 5(1)(b) of the Market Abuse Regulation and Article 2(3) of Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual trades in the Program are disclosed on the ST website (https://investors.st.com/stock-and-bond-information/share-buyback).

About STMicroelectronics
At ST, we are 50,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com.

For further information, please contact:

INVESTOR RELATIONS:
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41.22.929.59.20
[email protected]

MEDIA RELATIONS:
Alexis Breton        
Corporate External Communications
Tel: +33.6.59.16.79.08
[email protected]

C3375C -- Dec 1 2025 -- Disclosure of transactions in Own Shares PR_FINAL FOR PUBLICATION

Analyst’s Disclosure:I/we have a beneficial long position in the shares of HROW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryRoyal Gold is rated a buy, supported by a capital-light, high-margin business model and a robust dividend growth track record.The company's recent acquisitions, efficient operations, and balanced asset portfolio position it for strong cash flow and double-digit growth through 2027.Despite a 40% rally in 2025, RGLD trades at a 32% discount to fair value, offering 53% upside potential and 18%+ annual total returns.The dividend is well-covered, with a 25-year growth streak and low payout ratios, supporting further increases and sector-leading dividend consistency.Black Friday Sale 2025: Get 20% Offe-crow/iStock via Getty Images

Co-authored with Kody's Dividends

Seeking Alpha is constantly attracting new readers to the platform. At the risk of sounding like a broken record to longtime readers, I think it would be worthwhile for me to once again highlight

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Kody is long V and RGLD

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.

The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs. 

Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose – 5 milligrams – for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes. 

Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients. 

Eli Lilly's announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government's new direct-to-consumer website launching in January, TrumpRx. 

But Eli Lilly's deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval. 

That means Eli Lilly's Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly. 

"We will keep working to provide more options – expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need," said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement. 

With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject themselves. Eli Lilly first introduced that form of Zepbound in August 2024. 

It's unclear how many patients are currently taking single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound. 

Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic. 

The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. 

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PDX, VG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NobleCon is the preeminent showcase of small and microcap companies

, /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL.

To learn more about NobleCon and registration to attend or scheduling a one-on-one meeting with management please visit https://nobleconference.com/

About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC
Email: [email protected]
www.hoththerapeutics.com
Phone: (678) 570-6791

SOURCE Hoth Therapeutics, Inc.

Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies surge.

Peer To Peer Network launches “Intelligence Labs,” an AI-driven division delivering automated investor outreach, behavior-based segmentation, CEO-tone messaging, and AI booking tools.

Revenue target of $800K–$1M in 23 months; hitting this milestone triggers a public-company spinout, giving all PTOP shareholders proportional equity in the new AI entity.

Early enterprise traction underway, including advanced discussions with multiple companies and two active 90-day beta clients, with revenue expected to begin soon.

Cambridge, MA, December 1, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Peer To Peer Network (OTC: PTOP) today issued a summary of its November 27th investor call, where newly appointed division president Derek McCarthy outlined the Company’s AI-driven strategy for transforming investor communications and engagement. The Company opened the call by expressing its deep appreciation for the over two dozen shareholders who took time out of their schedules on the night before Thanksgiving to join the discussion.

Overview of PTOP Intelligence Labs

During the call, McCarthy introduced $PTOP Intelligence Labs, the Company’s newly launched AI division initially focused on serving publicly traded companies with smarter, faster, and more effective investor-marketing technology powered by AI. The platform is being engineered as a comprehensive solution that combines:

AI-powered audience identification
Automatically identifies, categorizes, and enriches investor-grade profiles across channels.
Behavior-based segmentation & scoring
Investors receive tailored content based on how they engage—clicks, reads, repeat visits, time on site, message opens, and more.
Automated, personalized communication
AI-generated messages written in the CEO’s tone deliver consistent outreach through email, LinkedIn, and in-platform chat.
AI appointment booking & follow-ups
Investors can automatically schedule calls with leadership while the AI handles reminders, follow-ups, and ongoing nurturing.

Top Shareholder Questions Asked & Addressed:

“How will PTOP Intelligence Labs aid the company revenue-wise?”

Chairman & CEO Joshua Sodaitis explained:

“From day one, Derek was given a clear, measurable mandate when we brought him on board and established PTOP Intelligence Labs as our new AI division. All revenue produced by PTOP Intelligence Labs will flow directly into a separate corporate account under PTOP’s tax ID, meaning every dollar generated is PTOP revenue and increases the value of the parent company. Derek’s target is aggressive: $800,000 to $1,000,000 in the next 23 months.

Here’s where it gets exciting for shareholders:
If PTOP Intelligence Labs hits that goal, we will spin the division out into its own publicly traded company. PTOP will launch, capitalize, and distribute equity in this new entity, with Derek serving as the Chairman & CEO of the spinout. And under standard spin-off structure, every PTOP shareholder would receive shares in the new public company, proportional to their current PTOP holdings.

In other words:

Intelligence Labs drives near-term revenue directly into PTOP
A successful revenue milestone triggers the formation of a second public company
PTOP shareholders get stock in BOTH companies
Creating a multiplier effect on long-term shareholder value

A spinout like this is a proven strategy used by major public companies to unlock hidden value, accelerate growth, and create two market-cap engines instead of one. If PTOP Intelligence Labs reaches its target, shareholders won’t just own a part of PTOP—they’ll own a stake in a brand-new AI-focused public company built from inside the PTOP ecosystem.

This is the type of value creation you typically only see with high-growth tech firms. We are building PTOP to be one of them.”

“How soon will PTOP Intelligence Labs be revenue-generating?”

President of PTOP Intelligence Labs, Derek McCarthy, responded:

“We’re already in advanced discussions with several companies, including a major media group exploring a white-label partnership for our AI technology. Based on our current pipeline, I expect revenue to begin very soon, and once the first contract closes, we will issue a formal announcement.”

Derek further explained that two customers are currently in a 90-day beta testing phase, evaluating our AI stack prior to full commercial rollout. Once those pilots convert to paid agreements, PTOP Intelligence Labs will begin generating recognized revenue, paving the way for broader adoption and additional enterprise deals already in discussion.

Advanced Features in Development

McCarthy also discussed several next-phase features currently in development, including:

AI-powered, company-specific search engines that allow investors to instantly locate filings, news, decks, updates, and FAQs.
CEO Avatar Video Highlights, enabling automatic creation of short, personalized video summaries after press releases—voiced and delivered by an AI avatar modeled after the company’s CEO.

“These features are designed to modernize investor relations and remove friction between the company and the shareholder,” McCarthy said. “We’re building an ecosystem that allows small-cap and mid-cap companies to communicate with investors at a level typically reserved for much larger issuers.”

Commitment to Investors & Closing the Year Strong

Peer To Peer Network reiterated its commitment to transparency, innovation, and constant improvement as it prepares additional updates before year-end.

“We appreciate every investor who joined us on Wednesday evening,” McCarthy added. “Your engagement drives our mission, and we look forward to sharing further progress and development milestones in the weeks ahead.”

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations, estimates, and projections about the industry, management’s beliefs, and certain assumptions made by the Company. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Actual outcomes and results may differ materially from what is expressed in or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, technological development risks, market conditions, financial constraints, competitive products, and regulatory factors. The Company undertakes no obligation to update or revise any forward-looking statements, whether due to new information, future events, or otherwise, except as required by law.

Media & Investor Relations Information:

Peer To Peer Network, Inc. (OTC: PTOP)

[email protected]

617-481-1971

www.ptopnetwork.com

Source: Peer To Peer Network, Inc.

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address episodes of fluid buildup at home, benefiting patients, providers and payorsPDUFA target action date of July 26, 2026 WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA seeking approval for FUROSCIX ReadyFlow™ Autoinjector (SCP-111), developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX® (furosemide) On-body Infusor for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD). The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026.

“The FUROSCIX ReadyFlow Autoinjector marks a key milestone in expanding patient options and improving care. By delivering treatment in under 10 seconds, the ReadyFlow Autoinjector has the potential to transform how adults with chronic heart failure or chronic kidney disease manage episodes of fluid buildup—providing faster relief, reducing hospital admissions, and lowering overall healthcare costs,” said Michael Castagna, PharmD, Chief Executive Officer at MannKind Corporation. “We are excited about the opportunity to bring this innovation forward and empower patients with greater convenience and control in their treatment journey.”

If approved, FUROSCIX ReadyFlow Autoinjector would provide a new option for patients with CHF or CKD to manage fluid buildup episodes from the convenience of their home rather than in a hospital setting. The FDA-approved FUROSCIX On-body Infusor was approved for adult patients with edema in chronic heart failure in 2022 and in chronic kidney disease in 2025. The ReadyFlow Autoinjector would reduce administration time from five hours to under 10 seconds.

The sNDA is supported by positive study results announced in August 2024. Furosemide via the ReadyFlow Autoinjector demonstrated a bioavailability of 107.3% (90% CI: 103.9 – 110.8), achieving the 90% confidence interval limit of 80 to 125 percent. Additionally, participants who utilized ReadyFlow Autoinjector had similar urine output, urinary sodium excretion and urinary potassium excretion at 6, 8, and 12 hours compared to IV furosemide, and was generally well tolerated with respect to injection site pain.

The study was an open-label, single-center, single-dose, randomized, two-way crossover study in 21 healthy volunteers, ranging in age from 45 to 80. Each subject completed the screening, baseline, treatment, and follow-up phases. Subjects were randomly assigned in a 1:1 ratio to one of two treatment sequences (IV furosemide followed by furosemide via the ReadyFlow Autoinjector, or vice versa).

About FUROSCIX

IMPORTANT SAFETY INFORMATION
FUROSCIX is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives. 

Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy.

Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.

Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide.

Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.

In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment.

Contact with water or other fluids and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure patients can detect and respond to alarms.

The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

Please see the full Prescribing Information (https://www.furoscix.com/wp-content/uploads/prescribing-information.pdf) and Instructions for Use (https://www.furoscix.com/wp-content/uploads/instructions-for-use.pdf).

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements about a potential regulatory action date, and statements regarding the potential benefits of the administration of furosemide via an autoinjector for providers, patients and payors. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that issues that develop in the review by the FDA may subject us to unanticipated delays or prevent us from obtaining marketing approval as well as other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including under the “Risk Factors” heading of its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

FUROSCIX is a registered trademark of scPharmaceuticals, a wholly owned subsidiary of MannKind Corporation.

MANNKIND is a registered trademark of MannKind Corporation.

Targa Resources agreed to acquire Stakeholder Midstream, which provides natural gas gathering and processing services in the Permian Basin, for $1.25 billion in cash.

, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Cepton, Inc. (NASDAQ: CPTN) ("Cepton" or the "Company") on behalf of investors who purchased or sold Cepton shares during the period of July 29, 2024 through January 6, 2025 (the "Class Period").

Investor Deadline: Investors who purchased or sold Cepton securities during the Class Period may, no later than December 8, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Cepton is a lidar technology company headquartered in San Jose, California. Having been acquired by Koito Manufacturing Co., Ltd. ("Koito") in January 2025, Cepton's stock is no longer publicly traded.

The lawsuit alleges that when seeking shareholder approval of Koito's merger proposal, which valued Cepton shares at $3.17 per share, Cepton and its senior executives failed to disclose the existence of a credible third-party acquisition bid that valued the Company at more than double the price of the Koito proposal.

Four months after the merger closed, former shareholders sued Cepton's senior officers in the Delaware Court of Chancery. In September 2025, when a redacted amended complaint filed in that Delaware action became publicly available, investors learned of the existence of documents indicating that the Company's proxy materials for the Koito acquisition had concealed material information from shareholders, including a competing bid.

According to the Delaware suit, Cepton's Board of Directors did not meaningfully explore the competing offer, nor did it disclose its terms when recommending that shareholders approve the Koito transaction. As a result, shareholders were denied a fair opportunity to assess the proposed deal. Furthermore, the Delaware complaint alleges that Cepton's CEO suffered from conflicts of interest with respect to the Koito proposal.

If you are a Cepton investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:
Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

Caitlin Adorni
Director of Portfolio & Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
[email protected] 

SOURCE Berger Montague

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Nature Genetics of a large genome-wide association study (GWAS) that used the company’s Proteograph® Product Suite to measure proteins at peptide-level resolution and map their genetic determinants. The study, led by Karsten Suhre, PhD, of Weill Cornell Medicine–Qatar, with collaborators from Harvard Medical School/Brigham and Women’s Hospital, Seer, and TruDiagnostic, provides the strongest evidence to date that mass spectrometry validation is essential for turning genomic signals into reliable drug targets and clinical biomarkers. Without mass spectrometry validation, as many as one-third of protein–gene associations reported by affinity-based assays do not replicate, highlighting the necessity of accuracy in proteogenomics.

The analysis included ~1,600 blood samples representing multiple ethnic backgrounds. A discovery cohort of 1,260 and an independent replication cohort of 325 were profiled using Seer’s Proteograph workflow. Across these samples, 5,753 proteins were detected, and 1,980 were quantified in at least 80 percent of participants.

From these data, the researchers identified 364 protein quantitative trait loci (pQTLs) genetic variants associated with protein abundance. Of these, 102 replicated in the independent cohort. 35 of the replicated signals were previously unreported, extending the catalog of genetic regulation of proteins.

Affinity reagents have been used in proteomics to measure a predetermined panel of proteins in large cohorts and have generated thousands of reported pQTLs. But when protein-altering genetic variants change the binding site of affinity reagents, these methods can register erroneous signals as the binding strength of the affinity reagent to the protein is diminished. These so-called epitope effects can produce apparent associations between protein expression and genetic variants that do not represent true biology.

By measuring proteins directly at the peptide level, the Proteograph’s mass spectrometry approach made it possible to test whether a genetic variant truly altered protein expression, mitigating the confounding epitope effect.

“The Proteograph platform made it possible to perform population-scale mass spectrometry proteomics with the depth and reproducibility needed for genetic association studies,” said Dr. Suhre. “By measuring proteins directly at the peptide level, we could distinguish true biological effects from assay artifacts—yielding a more reliable map from genes to proteins to disease pathways.”

To contextualize the findings, the study compared mass spectrometry results with two of the largest affinity-based proteomics resources. The comparison revealed a clear pattern:

pQTLs consistently reported across multiple affinity platforms were confirmed by mass spectrometry.
Up to one-third of associations reported by a single affinity platform did not replicate when tested by mass spectrometry. “This study demonstrates that mass spectrometry-based analysis is crucial for proteomics,” said Serafim Batzoglou, PhD, Chief Data Officer at Seer. “By providing peptide-level confirmation at scale, the Proteograph establishes protein measurements that lead to novel genetic associations and help annotate the accuracy of affinity-based pQTL predictions.”

For academic researchers conducting GWAS and Mendelian randomization studies, the message is direct: datasets built only on affinity reagents may contain a substantial fraction of associations that do not represent true protein abundance. Without validation, downstream analyses risk drawing causal inferences from epitope-induced artifacts.

For drug discovery and biomarker development, peptide-level validation strengthens confidence that selected targets represent genuine biology, not technical noise. Reliable associations reduce wasted effort and increase the likelihood that preclinical findings will hold in clinical settings.

For translational research, the study demonstrates how mass spectrometry and affinity reagents can be used together, with mass spectrometry stratifying the level of reliability of affinity-based predictions.

For patients, this rigor means a higher probability that tomorrow’s therapies are built on real biology. Together, they create a path toward comprehensive and trustworthy protein–genetic maps.

This publication marks the validation stage. The Nature Genetics study provides peer-reviewed evidence that mass spectrometry can systematically resolve artifacts and confirm which associations are robust.

The transformation comes in what this enables. As proteomics expands to larger populations and integrates with genomics, epidemiology, and clinical records, the utility of those datasets depends on accuracy. By anchoring discovery on peptide-level confirmation, Seer positions proteomics to become a population-ready science that supports drug targets, biomarkers, and translational medicine with the rigor required for clinical impact.

Article information

Title: A genome-wide association study of mass spectrometry proteomics using the Seer Proteograph platform
Journal: Nature Genetics, November 2025 (online)
Authors: Suhre K., Lasky-Su J., et al., including Seer scientists

About Seer

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.

Media Contact:
Patrick Schmidt
[email protected]

Investor Contact:
Carrie Mendivil
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ae65f47f-3263-4c92-ae93-f0f8d4ea62e4

SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that the company will host a live webcast on Monday, December 8, 2025, at 8:15 p.m. ET, to review new and updated clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton's tyrosine kinase (BTK) degrader program, bexobrutideg (NX-5948), and provide a corporate update.

December 01, 2025 07:00 ET

 | Source:

Syndax Pharmaceuticals, Inc.

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.

A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827

SNDX-G

December 01, 2025 07:00 ET

 | Source:

Tessera Therapeutics

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines and clinical development with Tessera’s pioneering Gene WritingTM and non-viral delivery platforms
TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced a global collaboration to develop and commercialize TSRA-196, Tessera’s lead investigational in vivo Gene Writing program for the treatment of alpha-1 antitrypsin deficiency (AATD), an inherited monogenic disease that can affect the lungs, liver, or both organs, and currently impacts approximately 200,000 people in the U.S. and Europe. TSRA-196 is designed to precisely correct the genetic mutation underlying AATD, with the goal of restoring production of functional alpha-1 antitrypsin (AAT) protein through a one-time, durable treatment option for patients. Tessera expects to file an Investigational New Drug and multiple Clinical Trial Applications for TSRA-196 with the U.S. Food and Drug Administration (FDA) by the end of the year.

The collaboration brings together Regeneron’s industry-leading capabilities in genetics and proven track record in advancing novel genetic medicines with Tessera’s innovative Gene Writing and proprietary non-viral delivery platforms. Under the terms of the agreement, the companies will share worldwide development costs and potential future profits relating to TSRA-196 equally. Tessera will receive $150 million, inclusive of a cash upfront payment and equity investment from Regeneron. Tessera is also eligible to receive additional near and mid-term development milestone payments totaling $125 million. Tessera will lead the initial first-in-human trial, while Regeneron will lead subsequent global development and commercialization.

“At Regeneron, we are strong believers in the power of genetics and genetic medicines to transform patients’ lives, and we have a robust portfolio of potential treatments to do just this,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. “Alpha-1 antitrypsin deficiency is a serious disease with limited treatment options today and is particularly well suited for Tessera’s gene editing approach. Together with Tessera, we have an opportunity to pioneer new frontiers in genetic medicine and redefine what is possible for AATD patients.”

“This collaboration underscores what we believe is a medically and commercially important opportunity to deliver transformative outcomes with a one-time, intravenously delivered genetic treatment for patients living with alpha-1 antitrypsin deficiency,” said Michael Severino, M.D., Chief Executive Officer of Tessera Therapeutics. “Tessera is on the cusp of a critical inflection point as we prepare to enter the clinic in the near term. We are excited to partner with Regeneron, a global leader in innovative biotechnology and genetic medicine, to accelerate the development of TSRA-196 and broaden its potential impact to patients in need.”

The collaboration builds on Tessera’s recent progress in advancing TSRA-196, including preclinical data presented at the American Society of Gene & Cell Therapy 28th Annual Meeting, which highlighted durable, high-fidelity genome editing of SERPINA1, the locus responsible for AATD, in mice and non-human primates following a single dose of TSRA-196, with high liver editing specificity, no germline or off-target editing, and favorable safety and tolerability using Tessera’s proprietary lipid nanoparticle delivery vehicle. These findings reinforce TSRA-196’s potential to correct the underlying genetic cause of AATD and support its advancement into clinical development.

This agreement is subject to customary closing conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States. 

About Alpha-1 Antitrypsin Deficiency (AATD)

AATD is an inherited monogenic disease that can affect the lungs, liver, or both organs. It is most often caused by mutations in the SERPINA1 gene, which encodes alpha-1 antitrypsin (AAT), a protein produced in the liver and secreted into the bloodstream to protect lung tissue from enzymes such as neutrophil elastase. In individuals with severe AATD, mutations in the Z allele cause AAT protein to misfold and accumulate in the liver, leading to toxic effects such as inflammation and fibrosis. At the same time, insufficient circulating AAT leaves the lungs vulnerable to progressive damage consistent with chronic obstructive pulmonary disease (COPD) and emphysema. An estimated 200,000 people in the U.S. and Europe carry two copies of the Z allele (PiZZ genotype), typically resulting in only about 15 percent of normal serum AAT levels. There are currently no FDA-approved therapies that address the underlying genetic cause of AATD, and treatment options remain limited to weekly intravenous augmentation therapy for patients with lung disease.

About Regeneron 

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. 

About Tessera Therapeutics

Tessera Therapeutics is pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, with the aim to unlock broad new therapeutic frontiers. Our Gene Writing platform is designed to write therapeutic messages into the genome by efficiently changing single or multiple DNA base pairs, precisely correcting insertions or deletions, or adding exon-length sequences and whole genes. Our proprietary lipid nanoparticle delivery platform is designed to enable the in vivo delivery of RNA to targeted cell types. We believe our Gene Writing and delivery platforms will enable transformative genetic medicines to not only cure diseases that arise from errors in a single gene, but also modify inherited risk factors for common diseases and create engineered cells to treat cancer and potentially autoimmune and other diseases. Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.

For more information about Tessera, please visit www.tesseratherapeutics.com.

Regeneron Forward-Looking Statements:

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, such as the planned clinical program in collaboration with Tessera Therapeutics, Inc. for TSRA-196, an investigational gene editing therapy for the treatment of alpha-1 antitrypsin deficiency, as discussed in this press release; the likelihood, timing, and scope of achieving any of the anticipated milestones described in this press release, including the filing of regulatory applications and the initiation of clinical trials for TSRA-196 as discussed in this press release; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), as well as Regeneron's collaboration with Tessera Therapeutics, Inc. discussed in this press release, to be cancelled or terminated; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including those to be conducted as part of the collaboration with Tessera Therapeutics, Inc. discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the planned studies discussed in this press release, on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as TSRA-196) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarterly period ended September 30, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. 
  
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Regeneron Contacts:

Investors:
Vesna Tosic
[email protected]

Media:
Ella Campbell
[email protected]

Tessera Contacts:

Investors:
Christina Zhang
[email protected]

Media:
Jonathan Pappas
LifeSci Communications, LLC
[email protected]

For investors seeking momentum, Virtus LifeSci Biotech Clinical Trials ETF (BBC - Free Report) is probably on the radar. The fund just hit a 52-week high and rose 181.9% from its 52-week low price of $13.42/share.

But, are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook to get a better idea of where it might head:

BBC in FocusThe LifeSci Biotechnology Clinical Trials Index is an equal weighted index that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. The product charges 79 bps in annual fees (See: All Health Care ETFs).

Why the Move?The biotech market has regained momentum lately, driven by favorable regulatory developments and cheaper valuations. The Fed’s rate cuts have also improved funding conditions, and the increasing adoption of AI in U.S. healthcare continues to provide a meaningful tailwind for the sector.

More Gains Ahead?Currently, BBC has a Zacks ETF Rank #3 (Hold) with a High risk outlook. However, it might continue its strong performance in the near term, with a positive weighted alpha of 76.63 (as per Barchart.com), which gives cues of a further rally.

Proof Of Concept Phase Complete – Production Shipments To Start December 2025

AmpliTech launches new Band 50 (n50) 5G Open RAN radios, engineered for long-range FWA coverage with low power consumption and full O-RAN 7.2x compatibility.

Successful field trials on a major LOI project, enabling the company to proceed to production and initial shipments starting December 2025.

Revenue outlook increases from $78M to over $100M, supported by multi-year deployments through 2027 and expanding rural broadband coverage.

HAUPPAUGE, N.Y., Dec. 01, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – AmpliTech Group, Inc. (NASDAQ: AMPG), a leading designer, developer, and manufacturer of state-of-the-art signal processing components, low-noise amplifiers (LNAs), and advanced 5G/6G ORAN systems, today announced formal release of its new Band 50 (n50) 5G Open RAN radios with capabilities to support large-scale 5G Fixed Wireless Access (FWA) network rollouts.

Band 50 (5G NR n50, around 1.4–1.5 GHz) is a coverage workhorse for new Open RAN-based FWA networks. AmpliTech’s n50 radios are designed to sit on towers, rooftops and poles across designated sites providing:

Wide-area 5G coverage over long distances, due to the relatively low 1.4 GHz frequency, which reaches farther and penetrates buildings better than higher mid-band spectrum.
High spectral efficiency and capacity for home broadband, with ample TDD bandwidth to support speeds up to 100 Mbps per household while serving many users per site.
Open, interoperable interfaces, built to O-RAN 7.2x fronthaul specifications so they can connect to multi-vendor Distributed Unit (DU) and Central Unit (CU) platforms in any Open RAN architecture.

Each Band 50 site required by the end user combines AmpliTech’s radios with any extensive fiber backbone and 5G core software, creating a highly cost-efficient FWA network specifically optimized for any rural or any challenging geography.

AmpliTech’s new Band 50 radios are designed specifically for Open RAN 5G FWA and macro deployments and offer:

O-RAN compliant 7.2x fronthaul, fully interoperable with leading DU/CU stacks.
High-efficiency RF front ends drawing on AmpliTech’s decades of low-noise amplifier (LNA) and RF design expertise.
Optimized 1.4–1.5 GHz performance for deep coverage and strong indoor penetration.
Compact, field-proven hardware designed to reduce power consumption and total cost of ownership.
A scalable architecture that can support three-sector macro sites and denser sectorization in high-traffic areas.

Strategic significance for AmpliTech

AmpliTech has formally completed its field trial with its end customer related to the current $78M LOI publicly released earlier this year. A ribbon cutting ceremony was held earlier this month, signaling our end customer’s approval to initiate production shipments and deployments. AmpliTech has in turn been given the long awaited green light to start shipping our production ready radios, which we will immediately commence in December 2025. Actual forecasts received from our end customer point out to an anticipated increase in total revenues from $78M to slightly over $100M, with shipments of our Band 50 radios to start early December and continuing throughout 2026 and 2027 fiscal years.

“This current Band 50 ORAN 5G radio release project is one of the most ambitious Open RAN and 5G FWA projects AmpliTech has put its sight on, and we are proud that AmpliTech’s research and development activities have placed our company at the forefront of ORAN 5G deployments in the world. Our mission has always been to use our RF and 5G expertise to efficiently connect more people. By releasing our new Band 50 ORAN 5G radios, we are helping delivery of fast and affordable 5G home broadband to FWA projects across the globe, which is exactly the kind of high-impact deployment we built this product line for. This initiative also underscores the strength of AmpliTech’s Open RAN strategy. Band 50 is a powerful coverage layer for emerging markets, and we see similar opportunities in other countries that want to combine digital-inclusion goals with vendor-diversified infrastructure.”

Fawad Maqbool, CEO/CTO of AmpliTech Group
About AmpliTech Group

AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGW) designs, develops, and manufactures advanced RF and microwave signal-processing components and systems for satellite, 5G/6G telecom, quantum computing, defense, and space applications. Its five divisions, AmpliTech Inc., Specialty Microwave, Spectrum Semiconductor Materials, AmpliTech Group Microwave Design Center, and AmpliTech Group 5G Divisions work symbiotically and serve customers worldwide. Through continuous innovation and U.S.-based manufacturing, AmpliTech is enabling the next generation of connectivity and communication systems. For additional information visit www.amplitechgroup.com and www.amplitech5g.com.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things, that company’s anticipated revenues are based on continuation of receipt of orders against signed LOI’s and positive market conditions. The words “may” “would” “will” “expect” “estimate” “anticipate” “believe” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements because of various factors. Other risks are identified and described in more detail in the “Risk Factors” section of the Company’s filings with the SEC, which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising these forward-looking statements, except as required by applicable law.

Contacts:

Corporate Social Media
X: @AmpliTechAMPG
Instagram: @AmpliTechAMPG
Facebook: AmpliTechInc
LinkedIn: AmpliTech Group Inc

Investor Social Media
Twitter: @AMPG_IR
StockTwits: @AMPG_IR

Company Contact:
Jorge Flores
Tel: 631-521-7831
[email protected]

Investor Relations Contact:
Kirin Smith
PCG Advisory, Inc.
[email protected]  

Source: AmpliTech Group, Inc. 

Black Friday sales rise, Bitcoin tumbles below $90,000 again, Thanksgiving travel disrupted, and more news to start your day.

Whitbread PLC's (LSE:WTB) Budget business rates hit has prompted brisk earnings downgrades from analysts, although both Deutsche Bank and Panmure Liberum keep the faith with 'buy' ratings.

The issue stems from new rateable values outlined by Rachel Reeves last week, which will push its business rate bill up by £40-£50 million in the first year. That scale of increase implies rateable values across the Premier Inn estate have more than doubled.

Deutsche’s Tim Barrett notes that hotels were always in the firing line. Headline data from the Valuation Office shows a 76% jump in rateable values for hotels as part of the latest revaluation, compared with rises of 29% for pubs, 14% for restaurants and 10% for general retailers.

What surprised the market was Whitbread’s disclosure that Premier Inn’s increase is roughly twice the hotel industry average. The group is expected to appeal many assessments and push for further cost savings, but the bank has still cut its profit forecasts.

Deutsche trims its profit forecast for FY27 and FY28 by 6% and 9% respectively and lowers its price target from 3,750p to 3,375p.

Panmure reaches a similar conclusion with slightly sharper numbers. It also assumes a £40-50 million hit to business rates in FY27 and folds that into a higher inflation outlook for the group, now 3.5-4.5% versus 2.0-2.5% for FY26.

On that basis, Panmure cuts its FY27 profit estimate by 11% to £441.4 million, while leaving FY26 untouched. Its price target comes down to 3,440p from 3,700p.

Both brokers stress that the revisions reflect the full economic impact as it stands today.

Panmure describes its forecasts as “fully loaded” for cost headwinds, leaving room for upgrades if trading proves stronger or if Whitbread can claw back more of the rates burden through mitigation.

Supply contraction in the wider hotel industry could also provide some support over time.

The shares fell 11.5% on Friday as investors digested the Budget implications. Even after the downgrades, the analysts argue the reaction looks heavy-handed.

Panmure’s revised target still implies close to 40% upside, while Deutsche’s maintains a clear valuation cushion. For now, the focus is on how many rate assessments Whitbread can challenge successfully and how quickly it can offset the hit through efficiencies.

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Freeport, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit.

Investors have until January 12, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Freeport securities. The case is pending in the U.S. District Court for the District of Arizona and is captioned Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243.

Why is Freeport Being Sued For Securities Fraud?

Freeport is a mining company with its Indonesian affiliate operating as PT Freeport Indonesia (“PTFI”). PTFI operates the Grasberg Copper and Gold Mine (“Grasberg”), in which the Indonesian government holds a commercial interest. During the relevant period, Freeport touted its safety procedures, including its use of data and technology as well as behavioral science principles to prevent fatal incidents. It indicated it provides the training, tools, and resources needed to identify risks and consistently apply effective controls.

As alleged, in truth, Freeport overstated its commitment to safety, given that it conducted unsafe mining practices at the Grasberg mine which were reasonably likely to result in worker fatalities.

Why did Freeport’s Stock Drop?

On September 9, 2025, Freeport issued a press release on its PTFI operations. It announced that mining operations in Grasberg had been suspended to evacuate seven team members that were trapped due to a landslide at one of its underground mines. This news caused the price of Freeport stock to drop $2.77 per share, or more than 5.9%, from a closing price of $46.66 per share on September 8, 2025, to $43.89 per share on September 9, 2025.

On September 24, 2025, Freeport issued an update on the incident noting that two of the seven individuals had been fatally injured and that the remaining five team members remained missing. In the same release, Freeport noted that due to the suspension in operations, sales were expected to be 4% lower for copper and approximately 6% lower for gold than July 2025 estimates. This news caused the price of Freeport stock to drop $7.69 per share, or almost 17%, from a closing price of $45.36 per share on September 23, 2025, to $37.67 per share on September 24, 2025.

Then, on September 25, 2025, Bloomberg reported that the incident and halt in production was straining the relationship between Freeport and Indonesia, that “the Jakarta government [had already been] looking to take greater control,” and that government officials may increase its demand for an increased share. This news caused the price of Freeport stock to drop $2.33 per share, or more than 6%, from a closing price of $37.67 per share on September 24, 2025, to $35.34 per share on September 25, 2025.

Finally, on September 28, 2025, an Indonesian news organization reported that the incident was preventable, not just a natural disaster. The article quotes an Indonesian professor stating that “the landslide, often termed a mud rush, is a known flow of mud and rocks from the mine cavity, a risk long associated with certain mining methods.” The professor stated, “[i]n other words, this danger is not new and should have been anticipated from the beginning[.]”

Click here for more information: https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit.

What Can You Do?

If you invested in Freeport you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

Investors have until January 5, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock. The case is pending in the U.S. District Court for the District of Minnesota and is captioned City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247.

Why is Inspire Being Sued For Securities Fraud?

Inspire develops and manufactures an implantable medical device for the treatment of sleep apnea. The latest version of the device is the Inspire V. The company announced FDA approval of Inspire V on August 2, 2024.

During the relevant period, Inspire repeatedly assured investors that it had taken all necessary steps to facilitate the launch of Inspire V and that it would launch the device as soon as sufficient inventory was available to meet supposedly high demand.

As alleged, in truth, Inspire failed to take basic steps to prepare clinicians and payors for the rollout, resulting in significant delays in adoption of the device. Moreover, the launch suffered from weak demand, as many customers already had excess inventory of the company’s older devices.

Why did Inspire’s Stock Drop?

On August 4, 2025, Inspire disclosed that the Inspire V launch was facing an “elongated timeframe” and as a result, it was reducing its 2025 earnings per share guidance by more than 80%. The company attributed the longer timeframe to a number of previously undisclosed factors including that many implanting centers “did not complete the training, contracting and onboarding required prior to the purchase and implant of Inspire V,” that certain “software updates for claims submissions and processing did not take effect until July 1, [2025]” which meant implanting centers could not bill for procedures until that date, and that demand for the Inspire V was poor because Inspire’s customers had a backlog of older versions of the company’s device.

On this news, the price of Inspire stock dropped $42.04 per share, or more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025.

Click here for more information: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

What Can You Do?

If you invested in Inspire you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

Investors have until December 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612.

Why Was MoonLake Sued for Securities Fraud?

MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab (“SLK”), an investigational therapeutic designed to treat adult participants with moderate to severe hidradenitis suppurativa (“HS”).

MoonLake told investors that its “strong clinical data,” including results from its Phase 2 MIRA trial, translate into “higher clinical responses for patients, and provide ample opportunity for differentiation of sonelokimab versus all competitors.” The Company also stated that SLK’s Nanobody structure differed in beneficial ways from traditional monoclonal antibody treatments from its competitors.

As alleged, in truth, the Company’s clinical data and Nanobody structure did not confer a superior clinical benefit over its competitors, calling into question the drug’s chances for regulatory approval and commercial viability.

The Stock Declines as the Truth Is Revealed

On September 28, 2025, MoonLake reported its week 16 results of the VELA Phase 3 trials. The Company reported disappointing results for both trials, with VELA-2 failing to meet its primary endpoint, calling into question the drug’s chances for regulatory approval and commercial viability. On this news, the price of MoonLake stock fell $55.75 per share, or nearly 90%, from $61.99 per share on September 26, 2025, to $6.24 per share on September 29, 2025, the following trading day.

Click here for more information: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

What Can You Do?

If you invested in MoonLake you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (NASDAQ: BYND) for potential violations of the federal securities laws.

If you invested in Beyond Meat, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation.

Why Is Beyond Meat Being Investigated for Securities Fraud?

Beyond Meat makes plant-based meat alternatives. In late 2023, the company went through a global operations review and depreciated certain long-lived assets. Beyond Meat said that these assets were recorded in assets held for sale in its consolidated balance sheet at the lower of their carrying value or fair value less costs to sell, and that there were no impairments.

BFA is investigating whether Beyond Meat inflated the value of certain long-lived assets.

Why Did Beyond Meat’s Stock Drop?

On October 24, 2025, Beyond Meat announced that it “expects to record a non-cash impairment charge for the three months ended September 27, 2025, related to certain of its long-lived assets,” which it “expected to be material.” On this news, the price of Beyond Meat stock dropped roughly 23%, from $2.84 per share on October 23, 2025 to $2.185 per share on October 24, 2025.

Then, on November 3, 2025, the company delayed its earnings announcement for 3Q 2025 as it needed more time to complete the impairment review. This news caused Beyond Meat stock to decline substantially during the trading day on November 3, 2025.

Finally, on November 10, 2025, Beyond Meat reported its 3Q 2025 Earnings. It announced that losses from operations was $112.3 million, which included a “$77.4 million in non-cash impairment charges related to certain of the Company’s long-lived assets.”

Click here for more information: https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation.

What Can You Do?

If you invested in Beyond Meat you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital for potential violations of the federal securities laws after SEC probe is revealed.

If you invested in Jefferies or Point Bonita, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

Why are Jefferies and Point Bonita being Investigated?

Jefferies is an investment banking and capital markets firm. Its trade finance arm is named Point Bonita Capital. Jefferies and Point Bonita were two of the closest banking and financing partners of First Brands Group, LLC, an auto parts supplier which collapsed into bankruptcy in September 2025.

On October 8, 2025, Jefferies announced that it and Point Bonita had approximately $715 million in exposure to First Brands’ receivables, which represents roughly 25% of Point Bonita’s trade finance portfolio. On this news, the price of Jefferies stock fell $4.66 per share, or about 8%, from $59.10 per share on October 7, 2025, to $54.44 per share on October 8, 2025. Investors are reportedly currently seeking redemptions from Point Bonita as well.

On November 27, 2025, it was reported that the SEC is seeking information about whether Jefferies gave investors in its Point Bonita fund enough information about their exposure to the auto business, which filed for bankruptcy in September with $12bn in debt. It was also reported that the SEC is also looking into internal controls and potential conflicts within and between different parts of the bank.

BFA is currently investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors in connection with this significant exposure to First Brands and the subsequent SEC probe into the company.

Click here for more information: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

What Can You Do?

If you invested in Jefferies or Point Bonita you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Attorney advertising. Past results do not guarantee future outcomes.